Global Parkinson’s Disease Treatment Market Growth (Status and Outlook) 2025-2031

According to this study, the global Parkinson’s Disease Treatment market size will reach US$ million by 2031.

Parkinson’s disease (PD) is a chronic and progressive disease, considered an idiopathic form, and accounts for roughly 80% of the cases of Parkinsonism—neurological disorders that lead to movement problems. While the exact cause of Parkinson’s disease is unknown, it may include a number of factors such as aging, environmental factors/exposures, and genetic predispositions.

United States market for Parkinson’s Disease Treatment is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

China market for Parkinson’s Disease Treatment is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

Europe market for Parkinson’s Disease Treatment is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

Global key Parkinson’s Disease Treatment players cover Teva, Roche, Prothena, Acorda Therapeutics, Voyager Therapeutics, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2024.

LPI (LP Information)' newest research report, the “Parkinson’s Disease Treatment Industry Forecast” looks at past sales and reviews total world Parkinson’s Disease Treatment sales in 2024, providing a comprehensive analysis by region and market sector of projected Parkinson’s Disease Treatment sales for 2025 through 2031. With Parkinson’s Disease Treatment sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Parkinson’s Disease Treatment industry.

This Insight Report provides a comprehensive analysis of the global Parkinson’s Disease Treatment landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Parkinson’s Disease Treatment portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Parkinson’s Disease Treatment market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Parkinson’s Disease Treatment and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Parkinson’s Disease Treatment.

This report presents a comprehensive overview, market shares, and growth opportunities of Parkinson’s Disease Treatment market by product type, application, key players and key regions and countries.

Segmentation by Type:
Oral
Transdermal
Subcutaneous
Intestinal Infusion

Segmentation by Application:
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Teva
Roche
Prothena
Acorda Therapeutics
Voyager Therapeutics
Impax Pharmaceuticals
UCB
AbbVie
MSD
Orion Pharmaceuticals
Intec Pharma
NeuroDerm
Adamas Therapeutics
Acadia
Sunovion
GSK

Please note: The report will take approximately 2 business days to prepare and deliver. Show more